Compare Stanley Black & Decker, Inc. (SWK) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs TG Therapeutics Inc — how do they compare? Stanley Black & Decker, Inc. trades at $88.57 (market cap $13.47B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays a 3.77% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Stanley Black & Decker, Inc. for 62 Days and TG Therapeutics Inc for 16 Days on average.
| SWK | TGTX | |
|---|---|---|
Market Cap | $13.47B | $8.16B |
Volume | 2,859,744 | 1,735,121 |
Sector | Industrials | Health |
52-Week High | $104.00 | $59.06 |
52-Week Low | $62.12 | $26.94 |
Typical Hold Time | 62 Days | 16 Days |
Enterprise Value | $17.63B | $8.37B |
Dividend Yield | 3.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $89.17, up 0.97% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and projected 2026 net income margin rising to 4.06%. Valuation metrics appear reasonable with P/E of 21.8 and P/S of 0.89, while analyst consensus leans neutral with 43% buy ratings and $93 price target.
SWK presents a mixed outlook with strong brand positioning and margin improvement initiatives offset by technical weakness and competitive pressures. The stock offers value characteristics with dividend stability but faces execution risks in achieving projected earnings growth. Near-term direction will depend on Q3 2026 results due November 4, 2026.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
